Literature DB >> 16910165

Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa.

Antonio Siniscalchi1, Luca Gallelli, Nicola B Mercuri, Guido Ferreri Ibbadu, Giovambattista De Sarro.   

Abstract

Many papers documented that Parkinson's disease (PD) patients treated with levodopa (L-dopa) shows elevated plasma homocysteine (Hcy) levels. Several lifestyle factors are able to influence plasma Hcy levels. We review the evidence that L-dopa therapy is related with an increase in plasma Hcy levels and that several behaviours could be able to cause changes in plasma Hcy concentrations. Therefore, there are reasons to suggest that a healthy lifestyle lowering Hcy may prevent this potential iatrogenic complication during L-dopa therapy. Moreover, at present, no controlled prospective studies have evaluated this phenomenon.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16910165     DOI: 10.1080/10284150600583446

Source DB:  PubMed          Journal:  Nutr Neurosci        ISSN: 1028-415X            Impact factor:   4.994


  6 in total

Review 1.  Therapeutic strategies for Parkinson's disease: the ancient meets the future--traditional Chinese herbal medicine, electroacupuncture, gene therapy and stem cells.

Authors:  Xuan Wang; Xi-Bin Liang; Feng-Qiao Li; Hui-Fang Zhou; Xian-Yu Liu; Jian-Jun Wang; Xiao-Min Wang
Journal:  Neurochem Res       Date:  2008-04-11       Impact factor: 3.996

2.  Hyperhomocysteinaemia and chronic venous ulcers.

Authors:  Stefano de Franciscis; Giovambattista De Sarro; Paola Longo; Gianluca Buffone; Vincenzo Molinari; Domenico M Stillitano; Luca Gallelli; Raffaele Serra
Journal:  Int Wound J       Date:  2013-02-19       Impact factor: 3.315

3.  Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.

Authors:  Eliseu Felippe dos Santos; Estela Natacha Brandt Busanello; Anelise Miglioranza; Angela Zanatta; Alethea Gatto Barchak; Carmen Regla Vargas; Jonas Saute; Charles Rosa; Maria Júlia Carrion; Daiane Camargo; André Dalbem; Jaderson Costa da Costa; Sandro René Pinto de Sousa Miguel; Carlos Roberto de Mello Rieder; Moacir Wajner
Journal:  Metab Brain Dis       Date:  2009-03-18       Impact factor: 3.584

Review 4.  Hyperhomocysteinemia as a Risk Factor and Potential Nutraceutical Target for Certain Pathologies.

Authors:  Caterina Tinelli; Antonella Di Pino; Elena Ficulle; Serena Marcelli; Marco Feligioni
Journal:  Front Nutr       Date:  2019-04-24

5.  Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management.

Authors:  Antonio Siniscalchi; Luca Gallelli; Angelo Labate; Giovanni Malferrari; Caterina Palleria; Giovambattista De Sarro
Journal:  Curr Neuropharmacol       Date:  2012-09       Impact factor: 7.363

6.  Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure.

Authors:  Birger Scholz; Marcus Svensson; Henrik Alm; Karl Sköld; Maria Fälth; Kim Kultima; Céline Guigoni; Evelyne Doudnikoff; Qin Li; Alan R Crossman; Erwan Bezard; Per E Andrén
Journal:  PLoS One       Date:  2008-02-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.